Sonoma Pharmaceuticals is in the drug manufacturers industry and is in the healthcare sector. The company CEO is Frederick Sandford. Sonoma Pharmaceuticals Inc is engaged in developing and commercializing differentiated therapies to patients living with chronic skin conditions. It develops solutions in to treat skin conditions, such as acne, atopic dermatitis, and scarring.

Previous Intraday Performance:

The SNOA shares had a previous change of -1.37% which opened at 0.77 and closed at 0.73. It moved to an intraday high of 0.77 and a low of 0.69.

SeekingAlpha:  Microcaps dominate midday movers

Historical Performance:

Over the last five trading days, SNOA shares returned -6.40% and in the past 30 trading days it returned -17.98%. Over three months, it changed -32.41%. In one year it has changed -80.69% and within that year its 52 week high was 3.39 and its 52 week low was 0.64. SNOA stock is 14.08% above its 52 week low.

Our calculations result in a 200 day moving average of 1.04 and a 50 day moving average of 0.86. Right now, SNOA stock is trading -29.79% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  XEC and PCG among premarket losers


The company has a market cap of $8.7m with 12.0m shares outstanding and a float of 8.7m shares. Trading volume was 44,420 shares and has experienced an average volume of 48,675 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Sonoma Pharmaceuticals was -3.17 which ended on 31st of March 2018.

Below was the last reported quarterly diluted earnings per share:

4thQtr 2018Reported 02-14-2019: -0.26
3rdQtr 2018Reported 11-08-2018: -0.44
2ndQtr 2018Reported 08-08-2018: -0.55
1stQtr 2018Reported 06-13-2018: -0.93
4thQtr 2017 -0.73

The long-term trend of the EPS is an important number as it indicates the present value of Sonoma Pharmaceuticals; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -29.40% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 11.50% of institutional ownership.

The beta was calculated to be 0.88.

SeekingAlpha:  XEC and PCG among premarket losers

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -77.07%, profit margin is -58.79%, price-to-sales is 0.61 and price-to-book is 0.66.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 3  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here